Summary
In patients with moderate, dietary noncorrigible hyperlipoproteinemia type IIb and ischemic heart disease, treatment with nicotinic acid is limited by the side effects of the drug. In 100 patients, 6-month treatment with nicotinic acid (n=50) or “essential” phospholipids (EPL); Lipostabil®, manufacturer: Rhône-Poulenc Rorer) (n=50) indicated comparable efficacy for both substances: Significant (p<.001) reductions of serum total cholesterol, low-density lipoprotein (LDL) cholesterol, and triglyceride values were similar in both groups, while nicotinic acid increased high-density lipoprotein (HDL) cholesterol significantly (p<.01) better than Lipostabil. A detailed analysis of ultracentrifugal lipoprotein profiles, hydroperoxide concentrations in LDL, and cholesterol-accepting properties of HDL in a small number of Lipostabil- and nicotinic acid-treated patients revealed favorable shifts in the lipoprotein profile, significant (p<.05) reductions of LDL hydroperoxides, and favorable increases of the most antiatherogenic HDL2b subfraction only in the Lipostabil-treated group. Clinically, both medications reduced the intensity and number of angina pectoris attacks per week (p<.05), but only Lipostabil-treated patients significantly (p<.05) increased their working capacity in the veloergometric test. Since in the nicotinic acid-treated group dropouts (nine patients, eight related to the drug) and side effects [14] exceeded those in the Lipostabil-treated group (two dropouts not related to the drug, no side effects), it is suggested that Lipostabil is a preferable alternative in the treatment of patients with moderate, dietary noncorrigible hyperlipoproteinemia IIb and ischemic heart disease.
Similar content being viewed by others
References
Lipovetsky BM, Konstantinov VO.Blood Cholesterol and the Human Heart. St. Petersburg: Nauka, 1993 (in Russian).
Keenan JM, Fontaine PL, Wenz JB, Myers S, Huang Z, Rispin CM. Niacin revisited. A randomized, controlled trial of wax-matrix sustained-release niacin in hypercholesterolemia.Arch Intern Med 1991;151:1424–1432.
Poumay Y, Ronveaux-Dupal MF. Rapid preparative isolation of concentrated low density lipoproteins and of lipoprotein-deficient serum using vertical rotor gradient ultracentrifugation.J Lipid Res 1985;26:1476–1480.
El-Saadani M, Esterbauer M, El-Sayed M. A spectrophotometric assay for lipid peroxides in serum lipoprotein using a commercial available reagent.J Lipid Res 1989;30:627–630.
Blanche P, Gong E, Forte T, Nichols A. Characterisation of human high-density lipoproteins by gradient gel electraphoresis.Biochim Biophys Acta 1981;665:408–419.
Plavinsky SL, Kuznetsov AS. Acception of cholesterol by high density lipoproteins estimated by simple test and factor analysis.Phys Chem Biol Med 1994;1:111–117.
Konstantinov VO, Lipovetsky BM, Kuznetsov AS, Lozovsky VT, Vasilyeva LE, Klimov AN. Essential phospholipids versus nicotinic acid in treatment of II-B hyperlipidemic patients with coronary heart disease. In: European Atherosclerosis Society, 62nd EAS Congress Abstracts. Jerusalem, Sept 5–9, 1993, p 31.
Klimov AN, Konstantinov VO, Lipovetsky BM, et al. Essential phospholipids and prevention of coronary heart disease (CHD). In: Third International Conference on Preventive Cardiology, abstract book. Oslo, June 27–July 1, 1993, p 591.
O'Brien BC, Andrews VG. Influence of dietary egg and soybean phospholipids and triacylglycerol on human serum lipoproteins.Lipids 1993;28:7–12.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Klimov, A.N., Konstantinov, V.O., Lipovetsky, B.M. et al. “Essential” phospholipids versus nicotinic acid in the treatment of patients with type IIb hyperlipoproteinemia and ischemic heart disease. Cardiovasc Drug Ther 9, 779–784 (1995). https://doi.org/10.1007/BF00879871
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00879871